Concert Pharmaceuticals has developed AVP-786 (CTP-786 or deuterated dextromethorphan) and reached a milestone under Avanir Pharmaceuticals collaboration.
Avanir completed first of a two-stage pharmacokinetic study of AVP-786 in healthy subjects
According to the interim data, a formulation of AVP-786 has a similar pharmacokinetic, safety and tolerability profile compared to AVP-923, a formerly investigated fixed dose combination of dextromethorphan hydrobromide and quinidine sulfate.
Avanir chief scientific officer Joao Siffert said, "We were able to successfully replicate the steady-state plasma levels of AVP-923, but with a substantially lower dose of quinidine."
According to the licensing deal, Concert is eligible for additional milestone payments on reaching predefined clinical, regulatory and commercial objectives in addition to sales based royalties on any products containing deuterium-modified dextromethorphan (d-DM).
Avanir will continue to carry out research and commercialization of d-DM compounds, including AVP-786.